Leukemia

Leukemia

An image of Dr. Jorge Cortes presenting AML and CML highlights from ASH 2025, featuring Dr. Rahul Gosain and Dr. Rohit Gosain, with a professional background related to hematology and oncology researc.

Leukemia

03/04/2026

AML and CML Highlights From ASH 2025

Jorge Cortes, MDRahul Gosain, MD, MBARohit Gosain, MD

Azacitidine and venetoclax combination therapy for AML, showcasing practice-changing insights from ASH 2025 presented by Jayastu Senapati and Uma Borate.

Leukemia

01/16/2026

Azacitidine in AML: Key Takeaways From the PARADIGM Study

Jayastu Senapati, MBBSUma Borate, MBBS

Advanced AML treatment discussing FLT3 inhibitors, menin targeting, and triplet regimens with experts Abhishek Maiti, MD, and Jorge Cortes, MD, in a clinical oncology-focused presentation.

Leukemia

01/01/2026

Targeted Combinations Transform AML Care

Abhishek Maiti, MDJorge Cortes, MD

1. Expert oncologists discussing future trends in chronic myeloid leukemia (CML) therapy and insights from key clinical trials including ASC4, OPTIC, and ASXL1 for 2025.

Leukemia

12/31/2025

ASH 2025 CML Highlights: Asciminib, Ponatinib Optimization, and Treatment Sequencing

Sawyer Bawek, DOFadi Haddad, MD

Bispecific antibodies and CAR T-cell therapy for emerging data in TP53-mutated AML and MDS, featuring experts Mycal Casey, DO, and Abishek Maiti, MD, at OncUpdates conference.

Leukemia

12/24/2025

Reviewing ASH 2025 Data for ALL and TP53-Mutated AML or MDS

Abhishek Maiti, MDMycal Casey, DO

1. Expert oncologists discussing treatment options for cancer, emphasizing Venetoclax-based regimens, targeted agents, and rapid molecular profiling for personalized therapy.

Leukemia

12/23/2025

Improving Venetoclax and Other Targeted Therapies in AML

Zachary Braunstein, MDJayastu Senapati, MBBS

Leukemia

12/20/2025

Ibrutinib Updates in CLL From ASH 2025

Mahesh Swaminathan, MB, MSVanthana Bharthi, MD

1. Expert insights on frontline BTK inhibitors and triplet therapy for CLL at ASH 2025, featuring Mahesh Swaminathan and Bita Fakhri.

Leukemia

12/18/2025

Breaking Down ASH 2025 Data on Frontline Pirtobrutinib in CLL

Bita Fakhri, MD, MPHMahesh Swaminathan, MB, MS

Non-covalent BTKi efficacy post-covalent BTKi or BCL-2 therapies in cancer treatment, featuring experts Claudia Villa Celi, MD, and Daniel Ermann, MD, for oncology research updates.

Leukemia

12/18/2025

Sequencing BTKi Therapies in Patients With CLL

Claudia Villa Celi, MDDaniel Ermann, MD

1. Two healthcare professionals, a male and female doctor, smiling against a city skyline at dusk, promoting oncology research updates on BTK inhibitors and therapy in CLL.

Leukemia

12/17/2025

SEQUOIA Trial Long-Term Data Support Second-Generation BTK Inhibitors in CLL

Catherine Coombs, MDDaniel Ermann, MD